当前位置: 主页 > 前沿技术 >

类风湿关节炎、脊柱关节炎和银屑病关节炎患者的量身定制一线生物

时间:2016-12-21 17:18 来源:日照仁爱风湿病医院 点击: 咨询在线专家

导读

类风湿关节炎、脊柱关节炎和银屑病关节炎患者的量身定制一线生物制剂疗法 2016-12-21 中华风湿 类风湿关节炎、脊柱关节炎和银屑病关节炎患者的量身定制一线生物制剂疗法 摘 要 目的 意大利量身定制疗法(ITABIO)专委会组织一个多学科专家组,制定一套类风湿...

类风湿关节炎、脊柱关节炎和银屑病关节炎患者的量身定制一线生物制剂疗法

2016-12-21 

 

 

类风湿关节炎、脊柱关节炎和银屑病关节炎患者的量身定制一线生物制剂疗法

 

 

摘      要

 

 

目的

意大利量身定制疗法(ITABIO)专委会组织一个多学科专家组,制定一套类风湿关节炎(RA)、脊柱关节炎(SpA)和银屑病关节炎(PsA)患者量身定制一线生物制剂治疗的循证决策意见。

 

 

方法

进行文献的系统回顾,寻找影响一线生物制剂选择因素的英文文献,包括药物疗效和安全性,给药途径,是否有预测治疗应答的生物标记物,单药治疗的需求,患者的社会-经济状况,生活习惯,文化水平,个性,女性的生殖能力和生育潜力,是否有共患病,感染和结核感染潜伏(LTBI)再激活的宿主相关风险因素,心血管(CV)风险,以及治疗成本。

 

 

结果

一些因素,如患者选药倾向于生物制剂,有潜在生育需求女性适合使用抗TNF单药治疗,以及肥胖患者可以剂量调整后静脉给药使得量身定制疗法对三种风湿疾病均有效。而且发现,伊娜西普(ETN)和英福利西单抗(IFX)生物仿制药治疗RA有更好的疗效-成本证据。所有生物制剂都可使用,即便在影响RA用药选择因素不存在的情况下。高感染风险或LTBI阳性会驱使患者选用阿巴西普(ABA)、妥珠单抗(TCZ)、或ETN。如果选择单药治疗,TCZ应当是首选。风湿因子(RF)和抗环瓜氨酸肽抗体(ACPA)高滴度会促使患者选择TCZ或ABA,而有CVD高风险的患者,则会选择抗TNF,优先ETN。出现前葡萄膜炎或炎性肠病会促使患者选择抗TNF单抗(抗TNFs MoAb)。对于PsA患者,如果有高感染和TB风险,首选优特克单抗(UTK),其次也可使用ETN。选择抗TNFs或UTK是由皮肤或关节病严重程度、附着点炎和指趾炎决定,但如果PsA伴随代谢综合症或高CV风险,则应该优选ETN。

 

 

结论

鉴于有多种生物制剂选择的影响因素,一线生物制剂治疗可能要在RA、SpA和PsA患者中进行优化。

 

原文

 

Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis

 

Abstract

   

Objective

A   multidisciplinary expert panel, the Italian board for the TAilored BIOlogic   therapy (ITABIO), was constituted to formulate evidence-based decisional   statements for the first-line tailored biologic therapy in patient with   rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis   (PsA).

   

Methods

Systematic   review of the literature to identify English-language articles on the   variables influencing the first-line biologic choice, including the efficacy   and safety of the drug, the route of administration, the availability of   response predictor biomarkers, the need of monotherapy, the patient   socio-economic status, lifestyle, cultural level, personality, fertility and   childbearing potential in women, the presence of comorbidities, the   host-related risk factors for infection and latent tuberculosis infection   (LTBI) reactivation, the cardiovascular (CV) risk, and costs.

 

Results

Some   variables, including the patients’ preference, the indication for anti-TNF   monotherapy in potential childbearing women, and the intravenous route with   dose titration in obese subjects resulted valid for all the three rheumatic   conditions. Further, evidence of a better cost-effectiveness profile for etanercept (ETN) and   biosimilar infliximab (IFX) in RA was found. Any biologic may be employed in absence   of choice driving factors in RA. Otherwise, a high infection risk or LTBI   positivity drive the choice toward abatacept (ABA), tocilizumab (TCZ), or ETN. TCZ should be the   first choice if monotherapy is required. High rheumatoid factor (RF) and anti-citrullinated   protein antibodies (ACPA) titers should drive the choice toward TCZ or ABA,   while in patients at high CVD risk anti-TNF choice, with preference for ETN, seems appropriate.   Presence of anterior uveitis or inflammatory bowel disease drives the choice   to monoclonal antibody anti-TNFs (MoAb anti-TNFs). In PsA, ustekinumab (UTK),   and to a lesser extent ETN,   represents the first choice in patients at high infection and TB risk.   Anti-TNFs or UTK choice is guided by skin or articular disease severity,   enthesitis, and dactylitis, whereas ETN should be preferred if metabolic syndrome or   high CV risk complicate PsA.

 

Conclusion

Taking   in account of multiple choice driving variables, first-line biologic therapy   may be optimized in patients with RA, SpA, and PsA.

 


上一篇:EULAR 2016关于中轴型脊柱关节炎管理建议

下一篇:没有了

相关推荐

类风湿性关节炎RA治疗在过去30年的巨大进展...【查看详细】

专家团队

Paul McCartney

陈书德主任

...[详细]

Paul McCartney

孙运太主任

孙运太男,1948年生,自幼受家庭熏陶,...[详细]

Paul McCartney

翟学臣主任

男,1932年生,老军医翟院长,1947年2...[详细]

Paul McCartney

张云忠教授主任

张云忠教授从事临床治疗工作四十余年,...[详细]

Paul McCartney

刘湘源教授主任

刘湘源教授情况简介 刘湘源,男,1968...[详细]

Paul McCartney

孙绪忠主任

孙绪忠,毕业于济南军区军医学校,现任...[详细]

Paul McCartney

尹德奎主任

从事临床医、教、研工作四十余年。对常...[详细]

Paul McCartney

陈世贵主任

  日照仁爱医院...[详细]